CD144 (VE-cadherin) Monoclonal Antibody (eBioBV13 (BV13)), Functional Grade, eBioscience™

Product Details

Size	50 µg	
Published Species	Mouse, Human	
Host/Isotype	Rat / IgG1, kappa	
Recommended Isotype Control	Rat IgG1 kappa Isotype Control (eBRG1), Functional Grade, eBioscience™	
Class	Monoclonal	
Туре	Antibody	
Clone	eBioBV13 (BV13)	
Conjugate	Functional Grade	
Form	Liquid	
Concentration	1 mg/mL	
Storage conditions	4° C	
RRID	AB_842778	

Applications	Tested Dilution	Publications
Western Blot (WB)	Assay-Dependent	4 Publications
Immunohistochemistry (IHC)	-	5 Publications
Immunohistochemistry (Frozen) (IHC (F))	Assay-Dependent	-
Immunocytochemistry (ICC/IF)	-	6 Publications
Flow Cytometry (Flow)	1 μg/test	11 Publications
ELISA (ELISA)	-	1 Publication
Immunoprecipitation (IP)	Assay-Dependent	-
ChIP assay (ChIP)	-	1 Publication
Functional Assay (FN)	Assay-Dependent	1 Publication
Peptide array (Array)	-	1 Publication

Product Specific Information

Description: The BV13 monoclonal antibody reacts with mouse VE-Cadherin (CD144). VE-Cadherin is a 120 kDa member of the type II Cadherin family, characterized by the presence of 5 extracellular cadherin domains (ECD), and anchored to the actin cytoskeleton through their cytoplasmic tail. VE-Cadherin mediates homophilic adhesion between neighbouring endothelial cells and is localized within specialized structures at cell-cell contacts, called adherens junctions. VE-Cadherin is expressed constitutively throughout the entire vasculature, and is required for numerous endothelial cell functions including migration, survival, contact-dependent growth inhibition and endothelial cell assembly into tubular structures. Furthermore, it is thought that VE-Cadherin+CD45- cells from the yolk sac or aorta-gonad-mesonephros (AGM) have the potential to give rise to hematopoietic cells.

Applications Reported: This eBioBV13 (BV13) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, immunoblotting (WB), and immunohistology staining of frozen tissue sections. Intravenous injection of BV13 has been shown to induce a concentration- and time-dependent increase in vascular permeability in the heart and lungs.

Applications Tested: This eBioBV13 (BV13) antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be

1

used at less than or equal to 1 μ g per test. A test is defined as the amount (μ g) of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

30 References

Western Blot (4)

Aging cell

Monomeric C-reactive protein via endothelial CD31 for neurovascular inflammation in an ApoE genotype-dependent pattern: A risk factor for Alzheimer's disease?

"Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 16-1441-82) in Western Blot" Authors: Zhang Z,Na H,Gan Q,Tao Q,Alekseyev Y,Hu J,Yan Z,Yang JB,Tian H,Zhu S,Li Q,Rajab IM,Blusztajn JK, Wolozin B,Emili A,Zhang X,Stein T,Potempa LA,Qiu WQ

Cell death & disease

Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy.

"Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 16-1441-82) in Flow Cytometry" Authors: Zhang L,He J,Wang J,Liu J,Chen Z,Deng B,Wei L,Wu H,Liang B,Li H,Huang Y,Lu L,Yang Z,Xian S,Wang L

Immunohistochemistry (5)

JCI insight Year Flow pattern-dependent mitochondrial dynamics regulates the metabolic 2022 profile and inflammatory state of endothelial cells. "Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 16-1441-82) in Immunohistochemistry"

Authors: Hong SG,Shin J,Choi SY,Powers JC,Meister BM,Sayoc J,Son JS,Tierney R,Recchia FA,Brown MD,Yang X, Park JY

The Journal of cell biology


VE-cadherin endocytosis controls vascular integrity and patterning during development.

"Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 16-1441-82) in Immunocytochemistry" Authors: Grimsley-Myers CM,Isaacson RH,Cadwell CM,Campos J,Hernandes MS,Myers KR,Seo T,Giang W,Griendling KK,Kowalczyk AP

View more IHC references on thermofisher.com

Year 2020

More applications with references on thermofisher.com



For Research Uge Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in offect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is imited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTES, EXPRESS OR INNELD, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTES OF MERCHANTABILITY, ITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINCEMENT. BUYER'S EXCLUSIVE EMEMPT POR NOV-CONFORMING PRODUCTS DURING THE WARRANT PERIOD IS LIMITED TO REPAR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BULGATION TO REPAR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BULGATION TO REPAR, REPLACE OR REFUND FOR THE RONCONFORMING PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (III) USUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. As THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE CARDPARINE (The documentation accompanying the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorizad commercial uses, in vitro diagnostic uses, or vitro or in vito thomanor or animals.

Year 2021

Year 2021

View more WB references on thermofisher.com

E-mail: CustomerCare@thermofisher.com